Millennium Management LLC Has $25.18 Million Stake in Amphastar Pharmaceuticals, Inc. $AMPH

Key Points

• Millennium Management LLC has increased its stake in Amphastar Pharmaceuticals by 238.5%, owning approximately 1.83% of the company's stock valued at $25.2 million.
• Several other hedge funds also boosted their positions in Amphastar, contributing to a total of 65.09% institutional ownership in the company.
• Analysts' ratings for Amphastar Pharmaceuticals show a mixed outlook, with two buy ratings and three hold ratings, and a consensus target price of $31.60.

Millennium Management LLC lifted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 238.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 868,551 shares of the company's stock after purchasing an additional 611,995 shares during the quarter. Millennium Management LLC owned approximately 1.83% of Amphastar Pharmaceuticals worth $25,179,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. TD Asset Management Inc increased its position in Amphastar Pharmaceuticals by 20.2% during the first quarter. TD Asset Management Inc now owns 2,212,142 shares of the company's stock worth $64,130,000 after buying an additional 371,856 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its holdings in Amphastar Pharmaceuticals by 11.5% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,263,598 shares of the company's stock valued at $36,632,000 after purchasing an additional 130,672 shares during the last quarter. Epoch Investment Partners Inc. grew its stake in Amphastar Pharmaceuticals by 14.5% in the 1st quarter. Epoch Investment Partners Inc. now owns 1,261,307 shares of the company's stock valued at $36,565,000 after buying an additional 160,034 shares during the last quarter. Boston Trust Walden Corp grew its stake in Amphastar Pharmaceuticals by 24.2% in the 1st quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company's stock valued at $35,241,000 after buying an additional 236,704 shares during the last quarter. Finally, Systematic Financial Management LP grew its stake in Amphastar Pharmaceuticals by 32.6% in the 1st quarter. Systematic Financial Management LP now owns 326,546 shares of the company's stock valued at $9,467,000 after buying an additional 80,198 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Up 2.6%

AMPH traded up $0.69 during trading on Wednesday, reaching $27.69. 481,202 shares of the stock were exchanged, compared to its average volume of 559,594. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.39 and a twelve month high of $53.96. The stock has a market cap of $1.29 billion, a P/E ratio of 10.34 and a beta of 0.80. The stock's 50 day moving average price is $25.93 and its two-hundred day moving average price is $25.57. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.21 and a current ratio of 3.29.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on AMPH. Piper Sandler lowered their price objective on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a research note on Friday, August 8th. Bank of America lifted their price objective on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a report on Tuesday, August 26th. Finally, Needham & Company LLC upgraded shares of Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price target on the stock in a research report on Tuesday, August 12th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $31.60.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.